Agilent Releases New SureSelect Human All Exon V8

Agilent Technologies has released SureSelect Human All Exon V8, a new exome design providing comprehensive content and updated coverage of human protein-coding regions from RefSeq, CCDS, and GENCODE databases. The design also includes coverage for the TERT promoter and difficult-to-capture exons that are often omitted by competing products.

The SureSelect Human All Exon V8 is available in three options to accommodate diverse research needs: Exome v8 for routine exome sequencing, v8 Clinical Plus for clinical research, and v8 UTR Plus for translational research. The design utilizes machine learning-based probe design and an improved probe-printing process, covering a 35.1 Mb target region of the human genome with an efficient end-to-end design size of 41.6 Mb.

This panel is engineered to deliver enhanced enrichment performance for more uniform coverage, enabling efficient and cost-effective exome sequencing. Agilent notes that large-scale manufacturing ensures consistent results over time, a critical requirement for clinical research laboratories. The company positions this as a benchmark exome for the genomics community.

Agilent states the new design is already supporting genetics research through integration with its Alissa Interpret software for variant interpretation. In cancer research, the improved sequencing efficiency and coverage are expected to help researchers identify critical genomic targets more effectively. The system can be automated on Agilent's Bravo and Magnis NGS Prep systems to handle high-throughput applications and reduce operational expenses.